Sartorius Stedim Biotech S.A.

Factors to consider:

• Company pays dividends (annually): last record date 2025-04-03, amount 0.74$ (Y0.33%)
• Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

• 2024-12-31 to 2025-12-31 estimated range: [150.04$, 245.55$]
• 2025-12-31 to 2026-12-31 estimated range: [152.98$, 249.02$]

Financial Metrics affecting the SDMHF estimates:

• Negative: with PPE of 101.9 at the end of fiscal year the price was high
• Positive: 7.61 < Operating profit margin, % of 13.33
• Positive: 42.77 < Shareholder equity ratio, % of 48.28 <= 64.37
• Positive: 1.84 < Return on assets ratio (scaled to [-100,100]) of 2.08
• Positive: -9.11 < Industry operating profit margin (median), % of -7.19
• Positive: 0 < Operating cash flow per share per price, % of 4.48
• Positive: Interest expense per share per price, % of 0.90 <= 3.31